WO1991019798A1 - Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof - Google Patents
Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof Download PDFInfo
- Publication number
- WO1991019798A1 WO1991019798A1 PCT/US1991/004335 US9104335W WO9119798A1 WO 1991019798 A1 WO1991019798 A1 WO 1991019798A1 US 9104335 W US9104335 W US 9104335W WO 9119798 A1 WO9119798 A1 WO 9119798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- vector
- gene
- nucleotides
- sufficient number
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 163
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 86
- 230000002950 deficient Effects 0.000 title abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 73
- 238000012546 transfer Methods 0.000 claims abstract description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 145
- 210000004027 cell Anatomy 0.000 claims description 124
- 239000002773 nucleotide Substances 0.000 claims description 82
- 125000003729 nucleotide group Chemical group 0.000 claims description 82
- 210000002845 virion Anatomy 0.000 claims description 48
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 47
- 230000008488 polyadenylation Effects 0.000 claims description 27
- 108700004026 gag Genes Proteins 0.000 claims description 26
- 101150098622 gag gene Proteins 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 23
- 108700004025 env Genes Proteins 0.000 claims description 20
- 108091081024 Start codon Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 238000011144 upstream manufacturing Methods 0.000 claims description 12
- 101150030339 env gene Proteins 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 101710177291 Gag polyprotein Proteins 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 108700004029 pol Genes Proteins 0.000 claims description 4
- 108700004030 rev Genes Proteins 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102100034353 Integrase Human genes 0.000 claims description 3
- 101710125418 Major capsid protein Proteins 0.000 claims description 3
- 108010078428 env Gene Products Proteins 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 108010043277 recombinant soluble CD4 Proteins 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 108010089520 pol Gene Products Proteins 0.000 claims description 2
- 101150098213 rev gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710150344 Protein Rev Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 101150088264 pol gene Proteins 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 24
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 230000000692 anti-sense effect Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 102100034349 Integrase Human genes 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 101710205625 Capsid protein p24 Proteins 0.000 description 12
- 101710177166 Phosphoprotein Proteins 0.000 description 12
- 101710149279 Small delta antigen Proteins 0.000 description 12
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 12
- 108020000999 Viral RNA Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 208000030507 AIDS Diseases 0.000 description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 241000713311 Simian immunodeficiency virus Species 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 6
- 241001068263 Replication competent viruses Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 101710121417 Envelope glycoprotein Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241001045988 Neogene Species 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108700010908 HIV-1 proteins Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000017960 syncytium formation Effects 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 101150098170 tat gene Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000003907 Cyclin I Human genes 0.000 description 1
- 108090000264 Cyclin I Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000713711 Primate lentivirus group Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101710132316 Transactivation protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- -1 rev Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention is directed to vectors including vectors comprising a packaging defective HIV provirus, a vector comprising a HIV packaging sequence and a gene to be transferred, the use of the packaging defective vectors to create HIV packaging defective cell lines, and the uses of the vectors and cell lines.
- the HIV provirus is an HIV-1 provirus.
- the human immunodeficiency virus (HIV-I, also referred to as HTLV-III, LAV or HTLV-III/LAV) is the etiological agent of the acquired immune deficiency syndrome (AIDS) and related disorders [Barre-Sinoussi, et al., Science 220:868-871 (1983); Gallo et al, Science 224:500-503 (1984); Levy et al., Science 225:840-842 (1984); Popovic et al., Science 224:497-500 (1984); Sarngadharan et al., Science 224:506-508 (1984); Siegal et al. , N. Enel. J. Med.
- AIDS acquired immune deficiency syndrome
- the disease is characterized by a long asymptomatic period followed by progressive degeneration of the immune system and the central nervous system.
- Studies of the virus indicate that replication is highly regulated, and both latent and lytic infection of the CD4 positive helper subset of T-lymphocytes occur in tissue culture [Zagury et al. , Science 231:850-853 (1986)].
- the expression of the virus in infected patients also appears to be regulated to enable evasion of the immune response.
- HIV-I Molecular studies of the regulation and genomic organization of HIV-I show that it encodes a number of genes [Ratner et al., Nature 313:277-284 (1985); Sanchez-Pescador et al., Science 227:484-492 (1985); Muesing et al. , Nature 313:450-457 (1985); ain-Hobson et al., Cell 40:9-17 (1985)].
- the other primate immunodeficiency viruses, HIV-2 and simian immunodeficiency virus (SIV) also share many of the same structural and regulatory genes such as gag, pol. env. tat, rev and nef [Guyader, M. , et al., Nature 326:662-669
- Retroviruses are typically classified as belonging to one of three subfamilies, namely oncoviruses, spu aviruses and lentiviruses. Infection by oncoviruses is typically associated with malignant disorders. These viruses typically contain a single-stranded, plus-strand RNA genome of approximately 8,000 to 10,000 nucleotides encompassing the pap, pol and env. genes, as well as long terminal repeat (LTR) sequences. Oncoviruses typically contain an oncogene. It is generally believed that spumaviruses are not pathogenic in vivo, although they induce foamy cytopathic changes in tissue culture. Infection by lentiviruses is generally slow and causes chronic debilitating diseases after a long latency period. These viruses, in addition to the gag, pol. and env genes possess a number of additional genes with regulatory functions.
- HIV human immunodeficiency viruses
- Retroviruses share features of the replicative cycle, including packaging of viral RNA into virions, entry into target cells, reverse transcription of viral RNA to form the DNA provirus, and stable integration of the provirus into the target cell genome [Coffin, J. , __ Gen. Virol. 42:1-26 (1979)].
- Replication-competent proviruses at a minimum, contain regulatory long terminal repeats (LTRs) and the gag, pro, pol. and env genes which encode core proteins, a protease, reverse transcriptase/RNAse H/integrase and envelope glycoproteins, respectively [J. Gen. Virol. 42, supra1.
- the LTRs contain cis-acting sequences important for integration, transcription and polyadenylation.
- the long terminal repeats (LTRs) of HIV contain cis-acting sequences that are important for integration, transcription and polyadenylation.
- the tat gene encodes a 14kD protein that is critical for HIV replication and gene expression [Rosen, C.A., et al., Nature 319:555-559 (1986);
- cis-acting sequences located between the 5' LTR and the gag gene initiation codon have been located which are necessary for. the efficient packaging of the viral RNA into virions [Bender, M.A. , et al, J. Virol 61:1639-1646 (1987), Katz, R.A. , et al, J. Virol 59:163-167 (1986), Mann, R. , et al, Cell 31:153-159 (1983), Pugatsch, T., et al, Virology 128:505-511 (1983), Watanabe, S., et al, Proc. Natl. Acad. Sci.
- Vectors containing the desired gene and packaging sequences were incorporated by packaging signal-deleted viruses generating virions capable of entry into certain cells.
- the signals needed for packaging of lentiviruses RNA were incorporated by packaging signal-deleted viruses generating virions capable of entry into certain cells.
- the packaging-defective provirus vector it would be possible to create packaging defective cell lines that could be used to investigate the packaging mechanism of the virus and to develop strategies to interfere with this packaging mechanism.
- the virions produced by such packaging negative proviruses could be used for vaccines and as a system for efficiently introducing a desired gene into a mammalian cell. It would also be useful to have a vector that could be selectively targeted to HIV target cells and could thus introduce a desired product into such cells.
- HIV packaging sequence corresponds to the region between the 5' major splice donor and the gag gene initiation codon (nucleotides 301-319). More preferably, this sequence corresponds to a segment just downstream of the 5' major splice donor, and about 14 bases upstream of the gag initiation codon. In one embodiment it is a 19 base segment having the sequence AAAAATTTTGACTAGCGGA.
- This vector can be used to transform a preselected cell line to result in an HIV packaging defective cell line.
- each vector does not have a sufficient number of nucleotides corresponding to nucleotides of the HIV genome between the 5' major splice donor and the gag gene to efficiently package HIV RNA. More preferably, each vector would not contain a sequence corresponding to an LTR sequence downstrea of the nucleotides corresponding to the HIV genes.
- each vector would contain a different marker gene.
- the transformed cell line would express HIV virions but would not be able to package HIV RNA into these virions.
- these virions could be used to generate antibodies, as a vaccine or as a method of transferring a desired gene product to a different cell line capable of infection by HIV.
- a second vector contains a preselected gene, a sufficient number of nucleotides corresponding to an HIV packaging sequence to package HIV RNA (HIV packaging sequence) , and is flanked on each side with a sequence corresponding to a sufficient number of HIV LTR nucleotides to be packaged by the HIV packaging sequence (HIV LTR sequences), wherein the HIV packaging sequence and HIV LTR sequences correspond to the same HIV genome.
- This vector can be used with the packaging defective vectors to transfer the desired preselected gene.
- the vector can be administered to an HIV infected cell and be packaged by the HIV virions being produced.
- the HIV infected cell can be in an individual. Combinations where the HIV packaging defective vector and HIV virus as a helper virus are used together are also described.
- the packaging sequences are located in a region from the 5' major splice donor to a site within the 5' most part of the gag gene.
- Figure 1 is a schematic of the HIV-1 genome from the 5' LTR to the gag initiation codon showing the 5' major splice donor (SD) and the site of the deletion in a vector representing one embodiment of this invention, pHXB PI.
- Figure 2a-e represents schematics of vectors representing various embodiments according to this invention.
- Figure 2a is a packaging defective vector, HXB ⁇ P1.
- Figure 2b is a packaging defective vector, HXB ⁇ Pl ⁇ env.
- Figure 2c is a packaging defective vector, pSVIIIenv 3-2.
- Figure 2d is a packaging proficient vector, HVB(SL3-Neo) .
- Figure 2e is a packaging proficient vector, HVB(SL3-Neo) .
- Figure 3 is a schematic of one preferred embodiment showing two packaging deficient vectors, HXB ⁇ Pl ⁇ env and pSVIIIenv 3-2.
- Figure 4 is a chart showing p24 Levels in Culture of Infected Jurkat Cells by vectors representing various embodiments of this invention.
- Figure 5a is an autoradiogram of the immunoprecipitation of 35SS--llaabbeelllleedd vviirraall pprrootteeiinn ffrroomm CCOOSS--11 cells transfected with pHXB ⁇ Pl DNA with AIDS patient serum.
- Figure 5b is an electron micrograph of COS-l cells transfected with pHXB ⁇ Pl showing virion particles of normal HIV-1 morphology.
- Figure 6 is an autoradiogram of immunoprecipitation of labelled viral proteins from Jurkat T cell lysates or supematants exposed to supematants from COS-l cells that were transfected or mock transfected.
- Figure 7 is an RNA dot blot test.
- Figure 8 is an autoradiogram showing the Sourthern blot of total DNA of G418-resistant Jurkat cells. Detailed Description of the Invention
- HIV packaging defective vectors and cell lines We have now discovered that it is possible to make HIV packaging defective vectors and cell lines. We have found that the region between the 5' major splice donor and the gag gene initiation codon in HIV viruses contains sequences necessary for packaging of HIV RNA into virions.
- RNA (the HIV packaging sequence) .
- sequences preferably correspond to the genome of HIV-1, HIV-2 and simian immunodeficiency virus (SIV) .
- SIV simian immunodeficiency virus
- the vector does not contain the HIV packaging sequence corresponding to the segment immediately downstream of the 5' major splice donor and just upstream of the gag gene initiation codon.
- the .vector could contain nucleotides ranging from about 14 bases to 2 bases upstream of the gag initiation codon (for example either the 14 upstream bases or 5 upstream bases) and still be packaging deficient.
- the vector does not contain a nucleotide sequence beginning about 9 bases downstream of the
- nucleotides 301-319 is sufficient to result in loss of packaging ability (See Figure 1). However, even smaller deletions in this region should also result in loss of packaging efficiencies. Indeed, it is expected that a deletion as small as about 5 base pairs in this region should remove packaging ability. Thus the size of a particular deletion can readily be determined based upon the present disclosure by the person of ordinary skill in the art.
- the vector should contain an HIV nucleotide segment containing a sufficient number of nucleotides corresponding to nucleotides of the HIV genome to express functional HIV gene products, but as aforesaid, should not contain a sufficient number of nucleotides corresponding to the region between the 5' major splice donor and the gag gene initiation codon to permit efficient packaging of the viral RNA into virions.
- HIV packaging defective cell lines it is preferred that such cell lines do not produce any infectious HIV.
- a cell line transformed by these packaging deficient vectors would have low infectivity because the cells are packaging defective, some RNA can still be packaged into the virion.
- the HIV nucleotide segment does not correspond to the entire HIV genome so that if some of the viral RNA is packaged into the virion, what is packaged will not be a replication competent virus.
- the vector would not contain sequences corresponding to an HIV LTR but would contain sequences corresponding to a promoter region and/or another genome's polyadenylation sequences. Selection of particular promoters and polyadenylation sequences can readily be determined based upon the particular host cell.
- the LTR which the sequences do not correspond to is the 3' LTR. For example, see Figure 3.
- one vector would include sequences permitting expression of HIV proteins upstream of env and the second vector would permit expression of the remaining proteins.
- one vector would contain an HIV nucleotide segment corresponding to a sufficient number of nucleotides upstream of the gag initiation codon to the env gene sequence to express the 5'-most gene products.
- the other vector would contain an HIV nucleotide segment corresponding to a sufficient number of nucleotides downstream of the gag gene sequence and including a functional env gene sequence.
- Such vectors can be chemically synthesized from the reported sequences of the HIV genomes or derived from the many available HIV proviruses, by taking advantage of the known restriction endonuclease sites in these viruses by the skilled artisan based upon the present disclosure ( Figure 3).
- a different marker gene to each vector, i.e., co-transfect a preselected cell line with these different vectors and by looking for a cell containing both markers, one would have a cell line that has been co-transfected with the two vectors.
- RNA corresponding to the entire viral sequences would not be packaged in these virions.
- a second vector would contain other HIV or SIV genes and contain a deletion in the packaging sequence and a deletion for the env gene.
- This vector would also not have a 3' LTR, but would have a polyadenylation sequence.
- a vector which would not contain a sufficient number of nucleotides corresponding to HIV packaging sequence to package HIV RNA, but would contain a nucleotide segment corresponding to a sufficient number of nucleotides corresponding to a sufficient number of nucleotides of the HIV gag and pol genes to express functional gag and pol products.
- this vector would also contain a sufficient number of nucleotides corresponding to a functional tat gene. The vector would not contain a sufficient number of nucleotides to encode a functional env protein.
- the vector would also contain nucleotides corresponding to other HIV regulatory genes to express functional gene products, such as vpr. vpu. vif, etc.
- Other combinations of vectors can also be prepared.
- a vector that does not contain a sufficient number of nucleotides to correspond to a functional gag gene, but would have a sufficient number of nucleotides to correspond to functional pol and env genes other vectors include one that does not contain a sufficient number of nucleotides to encode a functional pol protein, but would have a sufficient number of nucleotides to encode a different functional HIV protein, etc.
- the term a.sufficient number of nucleotides permits additions, deletions and substitutions as long as the claimed functional ability is not lost. For example, if one is referring to the functional ability of packaging HIV RNA then the resultant vector must have a sequence that can package HIV RNA.
- HIV-1 can be pseudotyped with the envelope glycoproteins of other viruses. [(Lusso, P., et al., Science 247:848-851 (1990)]. Consequently, one can prepare a vector containing a sufficient number of nucleotides to correspond to a functional env gene from a different retrovirus. Preferably, the 5' LTR of this vector would be of the same genome as the env gene. Such a vector could be used instead of an env packaging deficient vector to create virions. By such a change, the resultant vector system can be used in a wider host range.
- Virtually any cell line can be used.
- a mammalian cell line for example, CV-1, Hela, Raji, RD, SW480 or CHO cell lines.
- CV-1 a mammalian cell line
- Hela a mammalian cell line
- Raji a mammalian cell line
- RD a mammalian cell line
- SW480 CHO cell lines
- a different promoter than the 5' LTR i.e., replace the 5' LTR with a promoter that will preferentially express genes under its control in a particular cell line.
- the CMV promoter will preferentially express genes in CV-1 or Hela cells.
- the particular promoter used can be readily determined by the person of ordinary skill in the art, based upon the particular host cell line to be used.
- enhancer sequences can readily be determined by the person of ordinary skill in the art depending upon the host cell line.
- viral enhancer proteins such as those of herpes virus, hepatitis B virus, which act on HIV LTRs to enhance the level of virus product, or cellular transactivator proteins.
- Cellular transactivation proteins include NF ⁇ -B, UV light responsive factors and other T cell activation factors well known to the person of ordinary skill in the art.
- the cells By using a series of vectors that together would contain the complete HIV genome, one can create cell lines that produce a virion that is identical to the HIV virion, except that the virion does not contain the HIV RNA.
- the virions can readily be obtained from these cells. For example, the cells would be cultured and supernatant collected. Depending upon the desired use the supernatant containing the virions can be used or these virions can be separated from the supernatant by standard techniques. Typically, this would include gradiant centrifugation, filtering, etc.
- the virions can be used to generate an antigenic response to the HIV virions and because these virions are identical to the actual HIV virions, except that the interior of these virions do not contain the viral RNA, the vaccine created should be particularly useful.
- virions can also be used to raise antibodies to the virion that can then be used for a variety of purposes, e.g. screening for the virion, developing target system for the virions, etc.
- HIV packaging deficient cell lines can be extremely useful as a means of introducing a desired gene, for example, a heterologous gene into mammalian cells.
- virions could be used as an extremely efficient way to package desired genetic sequences into target cells infectable by HIV. This would be done by preparing a vector containing a nucleotide segment containing a sufficient number of nucleotides corresponding to the packaging nucleotides of the HIV virus (HIV packaging region) , a predetermined gene, and flanking the packaging sequence and the predetermined gene with sequences corresponding to a sufficient number of sequences from within and near the LTRs for packaging, reverse transcription, integration and gene expression.
- HIV packaging region HIV packaging region
- predetermined gene flanking the packaging sequence and the predetermined gene with sequences corresponding to a sufficient number of sequences from within and near the LTRs for packaging, reverse transcription, integration and gene expression.
- the packaging region used would preferably correspond to at least the region between the 5' major splice donor and just upstream of the gag initiation codon, more preferably the region between the 5' major splice donor and the Bal I site (2202 in HIV-1) in the gag gene.
- a sufficient number of HIV-1 sequences to be packaged, reverse transcribed, integrated and expressed in the target cells would inlclude the U3, R and U5 sequences of the LTRs, the packaging sequences, and some sequences flanking the LTRs (required for reverse transcription) . From the 5' LTR, the R and U5 regions would be included which, in
- HIV-1 extend from +1 to 183.
- LTR necessary for reverse transcription and packaging would extend from 183 to about 335. Although not wishing to be bound by theory, applicants believe the inclusion of additional sequences from the gag gene in the vector (up to the Bal I site, nucleotide 2202) should enhance packaging efficiency.
- the regions from the 3' LTR and the immediate flanking sequences to be included extend from about 8645 to about 9213 (U3 and R regions) . Analagous regions would be included in a vector based upon HIV-2 or SIV.
- this vector is used to transfeet one of the HIV packaging deficient cells, it is the nucleotide sequence from this vector that will be packaged in the virions.
- These "HIV packaged" genes could then be targeted to cells infectable by HIV. This method of transformation is expected to be much more efficient than current methods. Further, by appropriate choice of genes, one could also monitor the method of HIV infection.
- the vector could contain a sufficient number of nucleotides corresponding to both 5' and 3' LTRs of HIV-1, HIV-2 or SIV to be expressed, reverse transcribed and integrated, a sufficient number of nucleotides corresponding to an HIV packaging sequence to be packaged, for example a segment between the 5' major splice donor and just upstream of the gag initiation codon (e.g., nucleotide 381).
- the vector would also contain a sufficient number of nucleotides of the gene which is desired to be transferred to produce a functional gene (e.g., gene segment).
- the gene can be any gene desired, for example, the gene for neomycin phosphotransferase (Neo ) .
- the "gene” would express a product that adversely affects HIV replication or integration such as a trans-dominant inhibitor, anti-sense RNAs, catalytic RNAs or soluble CD4 derivative.
- the vector of the present invention can be used to target HIV target cells.
- Preferred promoters include viral promoters, such as SL-3, murine retroviral LTR, etc. Enhancers sequences are also preferably used in the vector.
- the desired gene can be inserted in the present vector, in either the sense or anti-sense orientation with respect to the
- the vector can contain more than one gene or pseudogene sequence, permitting the expression of multiple genes of interest.
- This vector can preferably be used with the packaging-defective vectors described above. In such a situation, one preferably uses HIV LTRs in the vector corresponding to the genome of the package-deficient vector to facilitate packaging efficiency. However, in addition to use with a packaging-deficient virus, this vector can also be used with helper virus for gene transfer. For example, when one wants to deliver a gene to treat an individual infected with AIDS, one could insert this vector into that individual and it would be incorporated into HIV virions being produced in that individual. This would facilitate the delivery of the desired gene to the appropriate target cell.
- trans-dominant inhibitors anti-sense RNAs, catalytic RNAs, or soluble CD4 derivatives which are also aimed at inhibiting HIV-1 functions critical for viral replication.
- HIV packaging defective cell lines can be used to study various stages of the HIV life cycle, both in vivo and in vitro systems by a system because the cells will express HIV cellular proteins, but will not package the RNA.
- FIG. 1 shows the 5' major splice donor (SD) and site of deletion in a vector described below, pHXB ⁇ Pl.
- SD 5' major splice donor
- pHXB ⁇ Pl pHXB ⁇ Pl.
- a 19 base-pair deletion in this region was created in an infectious HIV-1 proviral clone contained on the plasmid pHXBc2 of Fisher, A.G. , et al, Nature 316: 262-265 (1985).
- This plasmid also contains an SV40 origin of replication to allow efficient gene expression in COS-l cells.
- the mutation was produced by the site-directed mutagenesis as described in Kunkel, T.A. , et al, Methods in
- the mutated plasmid was designated pHXB ⁇ Pl.
- COS-l cells were maintained in Dulbecco's modified Eagle's medium DMEM (Hazelton Biologies, Lenexa) supplemented with 10% fetal calf serum (Gibco, Long Island, NY) and antibiotics.
- DMEM Dulbecco's modified Eagle's medium
- Jurkat cells were maintained in culture in RPMI 1640 with 10% fetal calf serum and antibiotics.
- Jurkat cells were preventatively treated for mycoplasma with B.M. Cyclin I and II and human serum two weeks prior to infection.
- DMEM Dulbecco's modified Eagle's medium
- DMEM Hemazelton Biologies, Lenexa
- fetal calf serum Gibco, Long Island, NY
- HXBc2 (gag "1" . pro + . pol + . vif + . vpr " . ____ ' , tat + , rev "1” . env + . nef " ) provirus was used in all plasmids was used in all plasmid and vector constructs.
- COS-l cells were transfected with the pHXBc2 and pHXB ⁇ Pl plasmids by the DEAE-dextran procedure [Lopata et al, Nucl. Acids Res. 12:5707-5717 (1984); Queen and Baltimore, Cell 33:741-748 (1983); (Sodroski, J., et al, Science 231:1549-1553 (1986) which are incorporated herein by reference] .
- COS-l cell lysates and supematants radiolabelled with 35S-cysteine
- COS-l cell transfected by pHXB ⁇ Pl was 60% of that measured in cells transfected with the HXBc2 vector (data not shown).
- COS-l cells transfected with pHXB ⁇ Pl were fixed 48 hours following transfection and examined by electron microscopy. Viral particles, including budding forms, of normal HIV-1 morphology were observed.
- Figure 5B is an electron micrographs of COS-l cells transfected with
- PHXB ⁇ Pl showing virus particles of normal HIV-1 morphology.
- supe atants from COS-l cells transfected with pHXBc2 and pHXB ⁇ Pl were filtered (0.2 / .) and RT measured.
- Supematants containing equal amounts of RT activity of mutant and wild-type viruses were added to Jurkat human T lymphocytes.
- the Jurkat cultures along with a mock-infected culture were maintained with medium changes every three days. At intervals aliquots of Jurkat cells were labelled and assessed for expression of HIV-1 proteins by immunoprecipitation with 19501 AIDS patient serum.
- Figure 6 shows immunoprecipitation of labelled viral proteins from Jurkat T cell lysates (lanes 1-3, 7-9 and 13-15) or supe atants (lanes 4-6, 10-12 and 16-18) exposed to supe atants from COS-l cells that were mock transfected (lanes 1, 4, 7, 10, 13 and 16), pHXBc2 (lanes 2, 5, 8, 11, 14 and 17), or transfected with pHXB ⁇ Pl (lanes 3, 6, 9, 12, 15 and 18) .
- the Jurkat cells were examined at day 7 (lanes 1-6), day 14 (lanes 7-12) and day 21 (13-18) following infection.
- Jurkat cultures exposed to HXB ⁇ P1 exhibited marked delays in and lower levels of viral protein production relative to those exposed to pHXBc2, the wild-type virus.
- Virus replication in human T lymphocytes transfected by HXB ⁇ P1 is thus seen to be significantly attenuated compared with cells transfected by HXBc2.
- Supematants from the above cultures were 0.2 -filtered and equivalent amounts of reverse transcriptase activity pelleted by centrifugation at 12000xg for one hour at 20°C.
- Viral pellets were lysed by NP40 in the presence of vanadyl ribonucleotides and dilutions of virus dot-blotted onto nitrocellulose filters.
- Some samples were treated with sodium hydroxide (5M at 60°C for 15 minutes) prior to dot-blotting. Filters were hybridized with a DNA probe consisting of HIV-1 gag and env gene sequences, washed and autoradiographed as previously described in
- Figure 7 is an RNA dot blot without (column 1) and with (column 2) sodium hydroxide treatment following blotting of filtered supematants from the Jurkat cultures.
- the supematants contained a reverse transcriptase activity of 5 x 10 4 cpm of HXB ⁇ P1 (row A) , 5 x 10 4 cpm of HXBc2
- a mutation in this region exhibits minimal effects on the ability of the provirus to produce proteins and virion particles following transfection, but markedly decreases the level of virion RNA and attenuates virus replication in a human CD4-positive lymphocyte line. HIV-1 replicates in cultured CD4-positive cells via cell-free transmission and cell-to-cell transmission, the latter involving the contact of infected and uninfected cells
- pHVB(SL3-Neo)sense (pHVB (SL3-Neo)) and pHVB (SL3-Neo)anti-sense (PHVB (SL3-Neo)) plasmids contain the coding sequence of the neo gene.under the control of the SL3-3 murine leukemia virus LTR, with polyadenylation signals derived from SV40.
- the ⁇ HVB(SL3-Neo)sense and pHVB(SL3-Neo) anti-sense plasmids contain complete 5' and 3' HIV-1 LTRs and flanking viral sequences nucleotides 183-381 near the 5' LTR and nucleotides 8504-8661 adjacent to the 3' LTR.
- a unique Bam HI site was inserted at the boundaries of the major deletion in the HXBc2 provirus (nucleotides 382 to 8593) , and the SL3 LTR-Neo transcription unit was cloned into this site in either the sense (pHVB(SL3-Neo)) or antisense (pHVB(SL3-Neo)) orientation with respect to the HIV-1 LTRs. All of the plasmids contained SV40 origins of replication. See Figure 2. These vectors include the 19 base pair sequence shown by deletion to be important for packaging viral RNA. The vectors cannot encode any of the HIV-1 gene products.
- the vectors contain an insert in which the SL3-3 murine retroviral LTR, which functions as an efficient promoter in T lymphocytes, promotes the expression of the neomycin phosphotransferase (Neo ) gene.
- the polyadenylation signals for the Neo transcript are provided by sequences from SV40. Numbers above the plasmid in Figure 2 indicate the nucleotide of the HXBc2 sequence that form the boundaries of provirus/insert.
- the SL3-3 murine leukemia virus LTR is indicated SL3.
- the position of the major 5' splice donor (SD) and gag gene initiation codon (pagATG) are shown in the figure.
- DMEM containing FCS and antibiotics was placed in COS-l cell cultures 12 hours after transfection.
- COS-l supematants were harvested and filtered through a 0.2 ⁇ m filter (Millipore) 72 hours post transfection.
- the p24 level in the COS-l supematants was determined by a p24 radioimmunoassay (Dupont) .
- Jurkat cells to be infected with virus were seeded into 6-well culture plates at a 2.5 X 10 cells per well in 2.5 ml of complete medium.
- Ten-fold serial dilutions of transfected COS-l supematants were then applied to each well and the virus allowed to ' absorb to the Jurkat cells at 37°C for 4 hours. After this the Jurkat cells were pelleted and resuspended in complete medium. Twenty-four hours later the medium was replaced by complete medium containing G418 (Gibco, NY) at an active concentration of 0.8 mg/ml and the cells dispensed into 24-well culture plates at 1.0 X 10 cells per well. Culture medium was changed every 4 days.
- the cells were washed in phosphate-buffered saline and diluted to a concentration of 0.5 viable cells per 100 ⁇ l medium. Then 100 ⁇ l of the cell suspension was dispensed into each well of a 96-well culture plate. Wells containing single cells were identified by phase contract microscopy and individual cells were expanded to 10 cells in complete medium containing 0.8 mg/ml G418.
- Genomic DNA was prepared from clones, digested with Sad and Southern blotted as previously described by Southern, E.M, J. Mol. Biol. 98:503-517 (1975). Southern blots were hybridized to a 3.3 Kb fragment containing the SL3 LTR, neo gene and SV40 polyadenylation sequences that had been labelled by random priming with oligonucleotides. Southern blots were washed under conditions of high stringency.
- the pHXB ⁇ Pl plasmid and the HIV-1 vectors were cotransfected into COS-l cells as described above. Table 1 shows that gag p24 protein of HIV-1 was detectable in the supernatant of these transfected cells on the third day after transfection.
- the filtered COS-l supematants were serially diluted and incubated with Jurkat lymphocytes, which were selected for G418-resistance.
- the number of G418-resistant Jurkat cells generated ranged from 10 to 10 per milliliter of COS-l supernatant, with the HVB(SL3-Neo)anti-sense vector yielding higher titers than the HVB(SL3-Neo)sense vector.
- No G418-resistant Jurkat cells were generated following incubation with supernatant derived from COS-l cells transfected with no DNA, the vectors alone, or the pHXB ⁇ Pl plasmid alone.
- the HXB ⁇ P1 provirus is not completely replication defective.
- the production of viral p24 antigen and the formation of syncytia were examined to determine the amount of infectious virus In the G418-resistant Jurkat cells.
- Figure 4 shows that HIV-1 p24 antigen was detectable in the supematants of the Jurkat cultures. Syncytium formation was visible and increased with time in these cultures, indicating the expression of the HIV-1 envelope glycoproteins in the target cells. The induction of significant cytophathic effect in these cultures made cloning of the G418-resistant Jurkat cells difficult, and further suggested the presence of replication-competent viruses in the target cells. See also Table 2.
- the pHXB ⁇ Pl ⁇ env plasmid is identical to the pHXB ⁇ Pl plasmid except that the provirus in the former contains a deletion in the env gene and contains a polyadenylation signal from SV40 in place of the 3' LTR.
- the pSVIIIenv3-2 plasmid encodes both rev and env genes of HIV-1 under the control of the HIV-1 LTR, with polyadenylation signals derived from SV40.
- p24 gag protein was measured in cell supematants and syncytia were scored up to 40 days following the initial infection. In all of the clones examined, no syncytia were observed and p24 antigen was undetectable. See Table 2. This indicates that no replication-competent virus was present in these G418-resistant Jurkat cells.
- a Syncytia were scored according to the following criteria: -, no syncytia observed; +, 1-5 syncytia/hpf; ++, 5-10 syncytia/hpf; +++, greater than 10 syncytia/hpf (hpf-high power field) .
- the packaging-defective HXB ⁇ P1 provirus can provide trans-acting viral functions required for the transfer of a HIV-1 vector to Jurkat lymphocytes.
- the transfer of vector sequences occurs in the apparent absence of replication-competent virus.
- the titers of recombinant virus in this helper virus-free context appear to be improved relative to those observed in the presence of replication-competent virus, probably because of the induction of significant cytopathic effects by the latter.
- the higher titer observed for the HVB(SL3-Neo)anti-sense vector relative to the HVB(SL3-Neo)sense vector in the presence of replication-competent virus may in part relate to a suppresive effect of anti-sense read-through transcripts from the SL3 promoter on helper virus replication.
- HIV-1 vector described herein provides a simple, efficient means of introducing individual genes of interest into potential HIV-1 target cells.
- HIV-1 can be pseudotyped with the envelope glycoproteins of other viruses, increasing the host range of these vectors is feasible. Given the ability of the wild-type HIV-1 genome to encode multiple gene products, these vectors are readily adaptable for the expression of multiple genes of interest in the target cells.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54074690A | 1990-06-20 | 1990-06-20 | |
US540,746 | 1990-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991019798A1 true WO1991019798A1 (en) | 1991-12-26 |
Family
ID=24156769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/004335 WO1991019798A1 (en) | 1990-06-20 | 1991-06-18 | Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0536234A4 (en) |
JP (1) | JP3264281B2 (en) |
CA (1) | CA2084659A1 (en) |
WO (1) | WO1991019798A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017118A2 (en) * | 1992-02-28 | 1993-09-02 | Syngenix Limited | Defective packaging non-oncoviral vectors based on mpmv and hiv |
WO1993020220A1 (en) * | 1992-03-27 | 1993-10-14 | Whitehead Institute For Biomedical Research | Non-infectious hiv particles and uses therefor |
EP0644946A1 (en) * | 1992-06-10 | 1995-03-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vector particles resistant to inactivation by human serum |
WO1998017815A1 (en) * | 1996-10-17 | 1998-04-30 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US5854038A (en) * | 1993-01-22 | 1998-12-29 | University Research Corporation | Localization of a therapeutic agent in a cell in vitro |
US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
EP0903981A1 (en) * | 1996-04-02 | 1999-03-31 | The Regents Of The University Of California | Design of novel highly efficient hiv based packaging systems for gene therapy |
US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO2001007646A2 (en) * | 1999-07-21 | 2001-02-01 | Martin Heinkelein | Method for quantization of the antiviral effect of antiviral active principles |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
US6312683B1 (en) | 1997-12-22 | 2001-11-06 | Oxford Biomedica (Uk) Limited | Equine infectious anemia virus vectors |
WO2002079464A2 (en) * | 2001-03-30 | 2002-10-10 | Syngenix Limited | Viral vectors |
US6942969B2 (en) | 1996-01-29 | 2005-09-13 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US7939326B2 (en) * | 2004-04-29 | 2011-05-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
-
1991
- 1991-06-18 CA CA002084659A patent/CA2084659A1/en not_active Abandoned
- 1991-06-18 JP JP51128291A patent/JP3264281B2/en not_active Expired - Lifetime
- 1991-06-18 EP EP19910912130 patent/EP0536234A4/en not_active Withdrawn
- 1991-06-18 WO PCT/US1991/004335 patent/WO1991019798A1/en not_active Application Discontinuation
Non-Patent Citations (8)
Title |
---|
Cell, Vol. 58, issued 14 July 1989, M.H. MALIM et al., "Functional Dissection of the HIV-1 Rev Trans-Activator-Derivation of a Trans-Dominant Repressor of Rev Function", pages 205-214, see entire article. * |
J. Virol., Vol. 62, No. 10, issued October 1988, "Identification of a Signal in a Murine Retrovirus that is Sufficient for Packaging of Nonretroviral RNA into Virions", pages 3802-3806, see entire article. * |
J. Virol., Vol. 63, No. 9, issued September 1989, A. LEVER et al., "Identification of a Sequence Required for Efficient Packaging of Human Immunodeficiency Virus Type 1 RNA into Virions", pages 4085-4087, see entire article. * |
J. Virol., Vol. 64, No. 5, issued May 1990, A. ALDOVINI et al., "Mutations of RNA and Protein Sequences Involved in Human Immunodeficiency Virus Type 1 Packaging Result in Production of Noninfectious Virus", pages 1920-1926, see entire article. * |
Mol. Cell. Biol., Vol. 6, No. 8, issued August 1986, A.D. MILLER et al., "Redesign of Retrovirus Packaging Cell Lines to Avoid Recombination Leading to Helper Virus Production", pages 2895-2902, see entire article. * |
Nature, Vol. 318, issued 05 December 1985, MARIMAN & R. TELLIER et al., "New strategies for AIDS therapy and prophylaxis", page 414, see entire letters to the editor. * |
See also references of EP0536234A4 * |
Virology, Vol. 167, issued December 1988, D. MARKOWITZ et al., "Construction and use of a Safe and Efficient Amphotropic Packaging Cell Line", pages 400-406, see entire article. * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
US5919458A (en) * | 1989-10-16 | 1999-07-06 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
WO1993017118A3 (en) * | 1992-02-28 | 1993-10-14 | Lever Andrew M L | Defective packaging non-oncoviral vectors based on mpmv and hiv |
WO1993017118A2 (en) * | 1992-02-28 | 1993-09-02 | Syngenix Limited | Defective packaging non-oncoviral vectors based on mpmv and hiv |
US6294165B1 (en) | 1992-02-28 | 2001-09-25 | Syngenix, Ltd. | Defective packaging non-oncoviral vectors based on HIV |
US5747307A (en) * | 1992-02-28 | 1998-05-05 | Syngenix Limited | Mason-Pfizer Monkey Retroviral packaging defective vectors |
WO1993020220A1 (en) * | 1992-03-27 | 1993-10-14 | Whitehead Institute For Biomedical Research | Non-infectious hiv particles and uses therefor |
EP0644946A4 (en) * | 1992-06-10 | 1997-03-12 | Us Health | Vector particles resistant to inactivation by human serum. |
EP0644946A1 (en) * | 1992-06-10 | 1995-03-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vector particles resistant to inactivation by human serum |
US5854038A (en) * | 1993-01-22 | 1998-12-29 | University Research Corporation | Localization of a therapeutic agent in a cell in vitro |
EP0681482B1 (en) * | 1993-01-22 | 2005-12-07 | University Research Corporation | Localization of therapeutic agents |
US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US7279279B2 (en) | 1996-01-29 | 2007-10-09 | Monogram Biosciences, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US6942969B2 (en) | 1996-01-29 | 2005-09-13 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
EP0903981A1 (en) * | 1996-04-02 | 1999-03-31 | The Regents Of The University Of California | Design of novel highly efficient hiv based packaging systems for gene therapy |
EP0903981A4 (en) * | 1996-04-02 | 2002-07-17 | Univ California | Design of novel highly efficient hiv based packaging systems for gene therapy |
AU725143B2 (en) * | 1996-10-17 | 2000-10-05 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US6669936B2 (en) | 1996-10-17 | 2003-12-30 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
WO1998017815A1 (en) * | 1996-10-17 | 1998-04-30 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US6312682B1 (en) | 1996-10-17 | 2001-11-06 | Oxford Biomedica Plc | Retroviral vectors |
EP1041152A1 (en) * | 1996-10-17 | 2000-10-04 | Oxford Biomedica (UK) Limited | Retroviral vectors |
GB2325003A (en) * | 1996-10-17 | 1998-11-11 | Oxford Biomedica Ltd | Rectroviral vectors |
GB2325003B (en) * | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
US6312683B1 (en) | 1997-12-22 | 2001-11-06 | Oxford Biomedica (Uk) Limited | Equine infectious anemia virus vectors |
US6727058B2 (en) | 1998-03-18 | 2004-04-27 | The Salk Institute For Biological Studies | Intergrase assay |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
WO2001007646A2 (en) * | 1999-07-21 | 2001-02-01 | Martin Heinkelein | Method for quantization of the antiviral effect of antiviral active principles |
WO2001007646A3 (en) * | 1999-07-21 | 2001-05-17 | Martin Heinkelein | Method for quantization of the antiviral effect of antiviral active principles |
WO2002079464A3 (en) * | 2001-03-30 | 2003-02-20 | Syngenix Ltd | Viral vectors |
WO2002079464A2 (en) * | 2001-03-30 | 2002-10-10 | Syngenix Limited | Viral vectors |
US7939326B2 (en) * | 2004-04-29 | 2011-05-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
Also Published As
Publication number | Publication date |
---|---|
EP0536234A1 (en) | 1993-04-14 |
EP0536234A4 (en) | 1993-09-15 |
JPH05508320A (en) | 1993-11-25 |
JP3264281B2 (en) | 2002-03-11 |
CA2084659A1 (en) | 1991-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5981276A (en) | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof | |
US5665577A (en) | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof | |
EP0386882B1 (en) | Packaging defective HIV provirus, cell lines, and uses thereof | |
Parolin et al. | Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes | |
Arya et al. | New human and simian HIV-related retroviruses possess functional transactivator (tat) gene | |
Lisziewicz et al. | Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. | |
Malim et al. | Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species. | |
Kornfeld et al. | Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses | |
Neumann et al. | Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function | |
Vaishnav et al. | The biochemistry of AIDS | |
Sodroski et al. | A second post-transcriptional trans-activator gene required for HTLV-III replication | |
Poznansky et al. | Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector | |
Reitz Jr et al. | Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene | |
Chesebro et al. | Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages | |
Westervelt et al. | Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo | |
Cheng-Mayer et al. | Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 | |
Srinivasakumar et al. | The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines | |
Balliet et al. | Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate | |
US6013516A (en) | Vector and method of use for nucleic acid delivery to non-dividing cells | |
US20020034502A1 (en) | Retroviral vectors | |
WO1991019798A1 (en) | Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof | |
Kim et al. | V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate | |
Mergia et al. | cis-acting regulatory regions in the long terminal repeat of simian foamy virus type 1 | |
Chen et al. | Characterization of an envelope mutant of HIV-1 that interferes with viral infectivity | |
Inoue et al. | Mechanisms associated with the generation of biologically active human immunodeficiency virus type 1 particles from defective proviruses. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991912130 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2084659 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991912130 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991912130 Country of ref document: EP |